[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity
Rhea-AI Filing Summary
United Therapeutics Corporation (UTHR) reported insider activity by its CFO and Treasurer on a Form 4. On 11/24/2025, the executive exercised 21,000 stock options at an exercise price of $146.03 per share, converting them into common stock. That same day, multiple blocks of common shares were sold in market transactions, with weighted average sale prices reported in ranges generally around $466.72 to $482.42 per share. After these transactions, the reporting person directly held 8,142 shares of United Therapeutics common stock. The filing notes that the option exercise and subsequent sales were carried out under a Rule 10b5-1 trading plan entered into on August 5, 2025, which is a pre-arranged plan intended to allow insiders to trade shares over time according to preset instructions.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 21,000 | $0.00 | -- |
| Exercise | Common Stock | 21,000 | $146.03 | $3.07M |
| Sale | Common Stock | 960 | $467.3519 | $449K |
| Sale | Common Stock | 1,850 | $468.2863 | $866K |
| Sale | Common Stock | 1,552 | $469.3386 | $728K |
| Sale | Common Stock | 2,919 | $470.2208 | $1.37M |
| Sale | Common Stock | 1,971 | $471.8802 | $930K |
| Sale | Common Stock | 1,788 | $472.7256 | $845K |
| Sale | Common Stock | 280 | $473.5446 | $133K |
| Sale | Common Stock | 1,560 | $475.1074 | $741K |
| Sale | Common Stock | 1,621 | $476.0921 | $772K |
| Sale | Common Stock | 2,989 | $477.2173 | $1.43M |
| Sale | Common Stock | 1,630 | $478.1359 | $779K |
| Sale | Common Stock | 315 | $478.731 | $151K |
| Sale | Common Stock | 640 | $480.7103 | $308K |
| Sale | Common Stock | 794 | $481.5541 | $382K |
| Sale | Common Stock | 131 | $482.2947 | $63K |
Footnotes (1)
- This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. This transaction was executed in multiple trades at prices ranging from $475.60 to $476.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $476.63 to $477.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $477.63 to $478.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $478.63 to $478.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $480.10 to $481.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $481.18 to $482.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $482.21 to $482.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $466.72 to $467.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $467.72 to $468.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $468.76 to $469.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $469.77 to $470.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $471.33 to $472.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $472.34 to $473.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $473.40 to $474.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $474.55 to $475.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
FAQ
What insider transaction did United Therapeutics (UTHR) report on this Form 4?
The Form 4 reports that United Therapeutics' CFO and Treasurer exercised 21,000 stock options on 11/24/2025 at an exercise price of $146.03 per share and sold portions of the resulting common shares in multiple market transactions the same day.
What was the exercise price of the United Therapeutics (UTHR) stock options?
The reported stock option exercise price was $146.03 per share for 21,000 options, which were exercised on 11/24/2025 into United Therapeutics common stock.
Was the United Therapeutics (UTHR) insider trading under a Rule 10b5-1 plan?
Yes. The filing states that the exercise of stock options and subsequent sale of shares were conducted pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025.
What role does the reporting person hold at United Therapeutics (UTHR)?
The reporting person is identified as an Officer of United Therapeutics, serving as CFO and Treasurer, and filed the Form 4 as an individual reporting person.
What derivative security was involved in this United Therapeutics (UTHR) Form 4?
The derivative security was a stock option on United Therapeutics common stock, with 21,000 underlying shares, an exercise price of $146.03, a date exercisable of 03/15/2020, and an expiration date of 03/15/2027. These options were exercised on 11/24/2025.